

## Hikma enters the Spanish generic injectables market, strengthening its European presence

**London, 20 May 2024** – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, is pleased to announce the establishment of HIKMA ESPAÑA, S.L.U. (Hikma Spain). This marks Hikma's official entry into Spain, which has a generic injectable market size of approximately \$860 million<sup>1</sup>.

In the year to date, Hikma has received 36 product approvals and launched 25 products in Spain. These span several therapeutic areas including cardiovascular, oncology, central nervous system and anti-infectives.

The entry into the Spanish market strengthens the Group's established and growing presence in Europe. This includes high-quality manufacturing plants in Portugal, Italy and Germany, which supply injectable products to North America, Europe, and Middle East and North Africa.

Hikma is already supporting the Spanish hospitals by providing key oncological molecules that are currently in shortage.

### **Dr Bill Larkins, President of Hikma Injectables commented:**

"The expansion into Spain is another important milestone in our global strategy to grow and strengthen our Injectables' commercial presence in Europe and around the world. We have an agile supply chain, a growing product portfolio and regional manufacturing capabilities, which will enable us to supply Spanish hospitals and their patients with the high-quality injectable medicines they need. We look forward to building our presence here."

### **Carola Warleta, Commercial Head, Hikma Spain commented:**

"We are launching the Spanish affiliate at a time when the hospital sector is in need of a reliable and quality supplier. I am confident in our ability to work hand in hand with healthcare professionals and authorities to provide high-quality and affordable medicines to patients in Spain."

-- ENDS --

### **Enquiries:**

#### **Hikma (Investors)**

Susan Ringdal +44 (0)20 7399 2760/ +44 (0)7776 477050  
EVP, Strategic Planning and Global Affairs

Guy Featherstone +44 (0)20 3892 4389/ +44 (0)7795 896738  
Director, Investor Relations

<sup>1</sup> IQVIA 2023 USD Sales. Generic Injectable, Hospital Sector.



Layan Kalisse  
Senior Associate, Investor Relations

+44 (0)20 7399 2788/ +44 (0)7970 709912

**Teneo (Press)**

Doug Campbell / Rob Yates

+44 (0)7753 136628/ +44 (0)7715 375443

**About Hikma**

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)  
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,100 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: [www.hikma.com](http://www.hikma.com)

©2024 Hikma Pharmaceuticals PLC. All rights reserved.